Skip to Content

Zytiga Approval History

FDA Approved: Yes (First approved April 28, 2011)
Brand name: Zytiga
Generic name: abiraterone
Dosage form: Tablets
Company: Centocor Ortho Biotech Inc.
Treatment for: Prostate Cancer

Zytiga (abiraterone acetate) is a CYP17 inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.

Development History and FDA Approval Process for Zytiga

DateArticle
Feb  8, 2018Approval Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Dec 10, 2012Approval FDA Expands Zytiga’s Use for Late-Stage Prostate Cancer
Apr 28, 2011Approval FDA Approves Zytiga for Late-Stage Prostate Cancer
Dec 21, 2010Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide